iSpecimen (ISPC) AI Stock Analysis

• Market Cap: $3.63M
• Dividend Yield: N/A
• Average Volume (3M): 8.88M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.64
• Revenue Growth: -67.73%
• EPS Growth: 58.35%
• Country: US
• Employees: 24
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Diagnostics & Research
• EPS (TTM): -0.42
• Shares Outstanding: 9,771,046
• 10 Day Avg. Volume: 698,577
• 30 Day Avg. Volume: 8,882,166
• PEG Ratio: >-0.01
• Price to Book (P/B): 0.57
• Price to Sales (P/S): 0.20
• P/FCF Ratio: -0.23
• Enterprise Value/Market Cap: 0.59
• Enterprise Value/Revenue: 0.64
• Enterprise Value/Gross Profit: 2.97
• Enterprise Value/Ebitda: -0.23
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 41 Neutral
• Price Target: $0.46 ▲(23.51% Upside)

iSpecimen's overall stock score is primarily impacted by its weak financial performance, characterized by declining revenues and profitability, and negative cash flows. Technical analysis indicates bearish momentum, further weighing on the score. Valuation metrics are unfavorable due to ongoing losses and lack of dividend yield. While the company has made some progress in regaining Nasdaq compliance, the risk of delisting due to low stock price remains a concern.

Positive Factors

Strategic Partnerships

These partnerships enhance access to diverse biospecimens, supporting revenue growth and strengthening market position in the long term.

Leadership Change

New leadership can drive strategic initiatives and operational improvements, potentially enhancing long-term business performance.

Nasdaq Compliance

Maintaining Nasdaq compliance ensures continued access to capital markets, supporting financial stability and investor confidence.

Negative Factors

Declining Revenue

Declining revenue indicates challenges in market demand or competitive positioning, potentially impacting long-term growth prospects.

Negative Cash Flows

Negative cash flows highlight liquidity challenges, limiting the company's ability to invest in growth and sustain operations.

Nasdaq Delisting Risk

Delisting risk could reduce market visibility and investor interest, impacting liquidity and access to capital.

iSpecimen Business Overview & Revenue Model

Company Description

iSpecimen (ISPC) is a technology-driven company that specializes in the procurement and supply of human biospecimens for research and clinical purposes. Operating at the intersection of healthcare and biotechnology, iSpecimen provides a platform that connects researchers and biopharma companies with a diverse and extensive network of biospecimen providers. The company focuses on accelerating medical research by offering a wide range of biospecimens, including blood, tissue, and urine samples, along with associated data, to facilitate studies in areas such as drug development, diagnostics, and personalized medicine.

How the Company Makes Money

iSpecimen generates revenue primarily through the sale of human biospecimens and associated data to researchers, pharmaceutical companies, and academic institutions. The company's revenue model is built on fees charged for the procurement and delivery of biospecimens, which can vary based on the type and quantity of samples requested. Key revenue streams include transactions for individual biospecimen orders, long-term supply agreements with biopharma companies, and collaborative projects that may involve custom sample collection services. Additionally, iSpecimen has established strategic partnerships with hospitals, clinics, and biobanks, enhancing its access to a wide array of biospecimens and driving growth in its revenue through increased sample availability and diversity.

iSpecimen Financial Statement Overview

Summary

iSpecimen faces significant financial challenges, including declining revenues, negative profitability, and cash flow issues. Despite some improvements in the balance sheet with reduced debt levels and improved equity ratios, the company's financial health remains weak, with persistent net losses and cash flow deficits. Strategic improvements are essential to stabilize and enhance financial performance.

Income Statement

The company has shown a declining trend in revenue and profitability. Gross Profit Margin decreased from 52.8% in 2020 to 42.9% in 2024. Net Profit Margins remain negative, with worsening EBIT and EBITDA margins, indicating operational inefficiency. Revenue has been declining from $11.13 million in 2021 to $9.29 million in 2024, showcasing negative growth.

Balance Sheet

The balance sheet reflects a relatively high level of debt with a Debt-to-Equity Ratio of 0.09 in 2024, reduced from previous years. However, the negative equity in prior years raises concerns about financial stability. The equity ratio improved to 35.4% in 2024 from negative figures in earlier years, indicating some improvement in financial health.

Cash Flow

The company has consistently negative operating and free cash flows, with a significant cash burn. The operating cash flow to net income ratio is negative, highlighting issues in converting income into cash. Although free cash flow improved slightly in 2024 compared to previous years, it remains negative, indicating continued challenges in liquidity.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	3.35M	9.29M	9.93M	10.40M	11.14M	8.18M
Gross Profit	722.54K	3.99M	5.11M	5.65M	5.89M	4.60M
EBITDA	-9.47M	-12.73M	-8.80M	-8.80M	-5.86M	-1.74M
Net Income	-11.53M	-12.50M	-11.10M	-10.25M	-8.96M	-4.65M
Balance Sheet
Total Assets	9.00M	9.35M	15.82M	24.62M	35.72M	6.21M
Cash, Cash Equivalents and Short-Term Investments	2.78M	1.88M	5.01M	15.31M	27.74M	695.91K
Total Debt	281.44K	312.17K	196.24K	185.85K	3.42M	12.77M
Total Liabilities	5.92M	6.04M	6.08M	4.31M	5.93M	33.49M
Stockholders Equity	3.07M	3.31M	9.74M	20.31M	29.79M	-27.28M
Cash Flow
Free Cash Flow	-6.79M	-8.30M	-10.55M	-9.01M	-11.71M	-1.39M
Operating Cash Flow	-6.76M	-8.26M	-5.81M	-5.82M	-10.67M	-288.38K
Investing Cash Flow	-1.07M	1.98M	-7.23M	-3.19M	-1.04M	-1.10M
Financing Cash Flow	8.86M	5.82M	70.89K	-3.42M	38.75M	2.03M

iSpecimen Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.37
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ISPC, the sentiment is Negative. The current price of 0.37 is below the 20-day moving average (MA) of 0.44, below the 50-day MA of 0.59, and below the 200-day MA of 1.03, indicating a bearish trend. The MACD of -0.06 indicates Negative momentum. The RSI at 31.52 is Neutral, neither overbought nor oversold. The STOCH value of 9.26 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ISPC.

iSpecimen Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
INBS	45 Neutral	$5.52M	-3.09	-223.45%	―	3.26%	65.96%
MYNZ	41 Neutral	$9.61M	―	―	―	―	―
ISPC	41 Neutral	$3.63M	-0.05	-296.20%	―	-67.73%	58.35%
BIAF	38 Underperform	$5.71M	-0.06	-245.18%	―	-27.66%	13.18%
CHEK	26 Underperform	$9.13M	―	―	―	―	―

iSpecimen Corporate Events

iSpecimen Regains Nasdaq Compliance as of November 2025

On November 28, 2025, iSpecimen Inc. received confirmation from the Nasdaq Listing Qualifications Staff that it now meets the continued listing requirements under Nasdaq Listing Rules. Previously, on June 4, 2025, the company was notified of non-compliance with the minimum stockholders’ equity, market value of listed securities, or net income requirements. However, as of September 30, 2025, iSpecimen reported stockholders’ equity of $3,072,711, regaining compliance and closing the matter.

iSpecimen Faces Nasdaq Delisting Notice for Stock Price

On November 19, 2025, iSpecimen Inc. received a notice from Nasdaq indicating that its common stock had fallen below the minimum bid price requirement of $1.00 per share for 30 consecutive business days, putting the company out of compliance with Nasdaq’s listing rules. The company has until May 18, 2026, to regain compliance by achieving a closing bid price of at least $1.00 per share for ten consecutive business days. If compliance is not regained, iSpecimen may seek an additional compliance period or face potential delisting, with options including a reverse stock split to address the deficiency.

iSpecimen Appoints Katharyn Field as New CEO

On November 7, 2025, iSpecimen Inc. announced significant leadership changes with the appointment of Ms. Katharyn Field as Chief Executive Officer, Secretary, and Treasurer, succeeding Mr. Robert Bradley Lim who resigned from these roles and the Board. Ms. Field, who has been serving as President since February 2025, brings extensive experience in strategy consulting and executive leadership, particularly in the cannabis industry. Additionally, Mr. Arphing (Tommy) Lee was appointed as an independent director, joining the Audit and Nominating and Corporate Governance Committees. The company emphasized that these leadership changes are not expected to disrupt operations, and the Board remains focused on executing the company’s objectives.

iSpecimen Approves Key Proposals in Stockholder Meeting

On October 30, 2025, iSpecimen Inc. held a special meeting of stockholders to vote on several key proposals. The company successfully approved a reverse stock split, an increase in authorized shares, and amendments related to private financing transactions and convertible securities, all of which are aimed at enhancing its financial flexibility and compliance with Nasdaq rules.